Feed / ONC

BeOne Medicines AG

ONC

Healthcare · 346.89 +1.5% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

BeOne Medicines AG's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 15 directly disclosed connections are confirming.

Company+1.5% todayVolume comparison unavailable
Market group0 of 1 activeOncology Biotech · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Monitor disclosures attributing changes in interest expense to the sale of future royalty liability, higher debt rates, or changes in capitalized interest at Hopewell.

Invalidation: The isolated read changes if ONC's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 15 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Monitor disclosures attributing changes in interest expense to the sale of future royalty liability, higher debt rates, or changes in capitalized interest at Hopewell.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations328
Usable filing statements104
Verified relationships15
Evidence supporting the case
  • Latest annual revenue changed +40.2% year over year.
  • Operating margin changed +23.3 percentage points in the latest annual period.
  • Net margin changed +22.3 percentage points in the latest annual period.
  • Operating cash flow covered net income at 3.93x in the latest annual period.
  • Credit and interest rates has repeated favorable evidence across 5 filings.
  • Product pipeline and R&D has repeated favorable evidence across 5 filings.
Evidence challenging the case
  • Diluted shares increased 7.8% in the latest annual period.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

346.89
6m+21.6%12m+10.5%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$1.2B+280.8%$-1.21+11.2%
2022-12-31$1.4B+20.4%$-1.49+11.2%
2023-12-31$2.5B+73.7%$-0.65+1.2%
2024-12-31$3.8B+55.0%$-0.47+0.9%
2025-12-31$5.3B+40.2%$0.19+7.8%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 5 filings
Interest expense increased resulting from interest expense recorded under the effective interest method related to the sale of future royalty liability, higher interest rates on debt balances and lower interest capitalized related to completion of certain pha…
10-Q · Aug 5, 2026
Foreign exchangemixed · 5 filings
For the six months ended June 30, 2025, other income, net was $12.1 million, primarily due to foreign exchange gains and government subsidy income, partially offset by unrealized losses on our equity investments.
10-Q · Aug 5, 2026
Product pipeline and R&Dpositive · 5 filings
Internal research and development expense increased $111.9 million, or 18.4%, to $718.4 million and was primarily attributable to the expansion of our global development organization and our clinical and preclinical drug candidates, as well as our continued e…
10-Q · Aug 5, 2026
Restructuring and cost reductionsmixed · 2 filings
Other Expense, Net Other expense, net for the year ended December 31, 2025 was $42.6 million, due to impairment losses recognized on our equity investments partially offset by government subsidy income and foreign exchange gains.
10-K · Feb 26, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 95.8× · EV/sales 95.1×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

346.89+1.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ONC. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ONC. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ONC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMGNAmgen Inc.partnerFeb 26, 2026

We will share in a portion of the royalties on annual ex-China net revenue from IMDELLTRA ® above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a f…

AMGNAmgen Inc.supplierAug 6, 2025

Purchase Commitments As of June 30, 2025, non-cancellable purchase commitments amounted to $130.1 million, of which $32.6 million related to minimum purchase requirements for supply purchased from contract manufacturers and $97.5 million related to binding pu…

Depended on by

ZYMEZymeworks Inc.partnerMay 7, 2026

We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ONC is currently a Leader in the organic co-movement group Oncology Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ONC; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.